... of a Functionally Deficient AAT Protein Variant by Protease Inhibitor (PI) Typing PI typing is performed by polyacrylamide ... Nomenclature In some publications, the term alpha-1-protease inhibitor is substituted for alpha-1 antitrypsin (AAT). PI* ...

... trimester, and 47% before conception). Most regimens were protease inhibitor–based triple therapy (82.5%). There were 50 ... found maternal exposure to combination ART with a protease inhibitor associated with increased risk of preterm delivery (<37 ...

... between long-term (>3 years) exposure to the protease inhibitor atazanavir and risk of myocardial infarction (RR, 0. ... 95% CI, 0.85 to 0.92]). 109 Protease inhibitor use but not non-NRTI use was associated ...

... L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral ... al. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012; ...

... MS Word, 32K) Evidence Table 3. Trials of protease inhibitors plus pegylated interferon and ribavirin (MS Word, 57K) Evidence Table 4. Quality rating: Trials of protease inhibitors plus pegylated interferon and ribavirin (MS Word, 33K) ...

... 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial ( ... J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin ...

... F, Cooper S, et al. The use of protease inhibitors in pregnancy: maternal and fetal considerations. Infect Dis ... al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? ...

... and triple therapy regimens with the recently approved protease inhibitors telaprevir and boceprevir, which are used in combination ... alfa-2a or alfa-2b), ribavirin, and a protease inhibitor (either telaprevir or boceprevir) compared with dual therapy ...